Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling

Ma X., Liu J., Zhu W., Tang M., Lawrence N., Yu C.

Narrative Review on Cardiovascular Disease, published in Adv Drug Deliv Rev (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Drug Deliv Rev (2018)
Reported sample size
—
Source database
Europe PMC
PMID
29935988
PMCID
PMC6226327
DOI
10.1016/j.addr.2018.06.011
Citations
260

Abstract (original English)

3D bioprinting is emerging as a promising technology for fabricating complex tissue constructs with tailored biological components and mechanical properties. Recent advances have enabled scientists to precisely position materials and cells to build functional tissue models for in vitro drug screening and disease modeling. This review presents state-of-the-art 3D bioprinting techniques and discusses the choice of cell source and biomaterials for building functional tissue models that can be used for personalized drug screening and disease modeling. In particular, we focus on 3D-bioprinted liver models, cardiac tissues, vascularized constructs, and cancer models for their promising applications in medical research, drug discovery, toxicology, and other pre-clinical studies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCardiovascular DiseasesTissue EngineeringDrug Evaluation, PreclinicalModels, BiologicalBiomimetic MaterialsBioprintingPrinting, Three-DimensionalPrecision Medicine

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research